If you're willing to speculate, Cramer wants you to know about the company behind this potential breakthrough cancer drug.
"I'm talking about Pharmacyclics," said Cramer, the maker of Ibrutinib." "Currently the drug is being studied as a treatment for different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma."
Results are quite promising. The clinical trial data for Ibrutinib has been very strong.
In fact results are so strong, "The Food and Drug Administration already considers Ibrutinib a breakthrough drug—that's the designation the FDA gives to drug candidates that it feels are transformational. And Ibrutinib has received this breakthrough drug designation three times over," Cramer said.
"If approved, Pharmacyclics plans to charge $125,000 a year for Ibrutinib, which sounds exorbitant but is actually pretty standard for these revolutionary cancer treatments. Based on that pricing, the analysts who just initiated coverage on Pharmacyclics at JP Morgan think this drug can do $6.5 billion in peak sales as a treatment for chronic lymphocytic leukemia and mantle cell lymphoma," Cramer said.